Genetic basis of phaeochromocytoma and paraganglioma

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 20, Issue 3, 2006, Pages 435-450

  Benn, Diana E ^a,b   Robinson, Bruce G ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

paraganglioma; phaeochromocytoma; succinate dehydrogenase subunit B (SDHB); succinate dehydrogenase subunit C (SDHC); succinate dehydrogenase subunit D (SDHD)

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADRENALIN; CALCIUM; NEUROFIBROMIN; NORADRENALIN; NORMETADRENALIN; PARATHYROID HORMONE; PHENYLETHANOLAMINE N METHYLTRANSFERASE; PROTEIN RET; SUCCINATE DEHYDROGENASE; VON HIPPEL LINDAU PROTEIN;

ABDOMINAL SCINTISCANNING; ANAMNESIS; BIOCHEMISTRY; BLOOD PRESSURE MEASUREMENT; CARCINOGENESIS; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; FAMILIAL CANCER; FOLLOW UP; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GERM LINE; HEREDITY; HETEROZYGOSITY; HUMAN; HYPERPARATHYROIDISM; KIDNEY CARCINOMA; MISSENSE MUTATION; MULTIPLE ENDOCRINE NEOPLASIA; MUTATIONAL ANALYSIS; NEUROFIBROMATOSIS; NEUROMA; NONSENSE MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PENETRANCE; PHEOCHROMOCYTOMA; PHYSICAL EXAMINATION; RELATIVE; REVIEW; SYMPTOM; THYROID MEDULLARY CARCINOMA; THYROID NODULE; URINALYSIS; VALIDATION PROCESS; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; ALGORITHMS; GENETIC SCREENING; GENETIC TESTING; GERM-LINE MUTATION; HETEROZYGOTE DETECTION; HIPPEL-LINDAU DISEASE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEUROFIBROMATOSIS 1; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SYNDROME; VON HIPPEL-LINDAU DISEASE;

EID: 33748484479     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2006.07.005     Document Type: Review

References (81)

1. Dluhy R.G. Pheochromocytoma - death of an axiom. The New England Journal of Medicine 346 (2002) 1486-1488
2. Lenders J.W., Eisenhofer G., Mannelli M., et al. Phaeochromocytoma. Lancet 366 (2005) 665-675
3. Lack E.E. Tumors of the adrenal gland and extra-adrenal paraganglia. In: Rosai J., and Sobin L.H. (Eds). Atlas of Tumor Pathology (1997), Armed Forces Institute of Pathology, Washington 223-259
4. Histological typing of endocrine tumours. In: Solcia E., Klöppel G., and Sobin L.H. (Eds). World Health Organization International Histological Classification of Tumours. 2nd edn. (2000), Springer, London 38
5. Van Houtum W.H., Corssmit E.P., Douwes Dekker P.B., et al. Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. European Journal of Endocrinology 152 (2005) 87-94
6. Goldstein R.E., O'Neill J.A., Holcomb G.W., et al. Clinical experience over 48 years with pheochromocytoma. Annals of Surgery 229 (1999) 755-764
7. Plouin P.F., and Gimenez-Roqueplo A.P. The genetic basis of pheochromocytoma: who to screen and how?. Nature Clinical Practice. Endocrinology and Metabolism 2 (2006) 60-61
8. Neumann H.P., Bausch B., McWhinney S.R., et al. Germ-line mutations in nonsyndromic pheochromocytoma. The New England Journal of Medicine 346 (2002) 1459-1466
9. Wautot V., Vercherat C., Lespinasse J., et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Human Mutation 20 (2002) 35-47
10. Dannenberg H., Komminoth P., Dinjens W.N., et al. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas. Endocrine Pathology 14 (2003) 329-350
11. Santoro M., Carlomagno F., Romano A., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 267 (1995) 381-383
12. Songyang Z., Carraway K.L., Eck M.J., et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373 (1995) 536-539
13. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. The Journal of the American Medical Association 276 (1996) 1575-1579
14. Mulligan L.M., Marsh D.J., Robinson B.G., et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. Journal of Internal Medicine 238 (1995) 343-346
15. Nguyen L., Niccoli-Sire P., Caron P., et al. Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. European Journal of Endocrinology 144 (2001) 37-44
16. Bryant J., Farmer J., Kessler L.J., et al. Pheochromocytoma: the expanding genetic differential diagnosis. Journal of the National Cancer Institute 95 (2003) 1196-1204
17. Eisenhofer G., Walther M.M., Huynh T.T., et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 1999-2008
18. Jimenez C., and Gagel R.F. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Hormone & IGF Research 14 (2004) S150-S157
19. Machens A., Brauckhoff M., Holzhausen H.J., et al. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 3999-4003
20. Latif F., Tory K., Gnarra J., et al. Identification of the von-Hippel-Lindau disease tumor suppressor gene. Science 260 (1993) 1317-1320
21. Iliopoulos O., Levy A.P., Jiang C., et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 10595-10599
22. Iwai K., Yamanaka K., Kamura T., et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 12436-12441
23. Kamura T., Koepp D.M., Conrad M.N., et al. Rbx 1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284 (1999) 657-661
24. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
25. Hoffman M.A., Ohh M., Yang H., et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Human Molecular Genetics 10 (2001) 1019-1027
26. Lonser R.R., Glenn G.M., Walther M., et al. von Hippel-Lindau disease. Lancet 361 (2003) 2059-2067
27. Walther M.M., Reiter R., Keiser H.R., et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. The Journal of Urology 162 (1999) 659-664
28. Iliopoulos O. von Hippel-Lindau disease: genetic and clinical observations. In: Dahia P.L.M., and Eng C. (Eds). Genetic Disorders of Endocrine Neoplasia. Frontiers of Hormone Research Series (2001), Karger, Basel (Switzerland) 131-166
29. Walther M.M., Herring J., Enquist E., et al. von Recklinghausen's disease and pheochromocytomas. The Journal of Urology 162 (1999) 1582-1586
30. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287 (2000) 848-851
31. Niemann S., and Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics 26 (2000) 268-270
32. Astuti D., Latif F., Dallol A., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics 69 (2001) 49-54 [Erratum in: American Journal of Human Genetics 2002;70:565.]
33. Briere J.J., Favier J., Benit P., et al. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Human Molecular Genetics 14 (2005) 3263-3269
34. Bourgeron T., Rustin P., Chretien D., et al. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nature Genetics 11 (1995) 144-149
35. Scheffler I.E. Molecular genetics of succinate: quinone oxidoreductase in eukaryotes. Progress in Nucleic Acid Research and Molecular Biology 60 (1998) 267-315
36. Ackrell B.A., Johnson M.K., Gunsalus R.P., et al. Structure and function of succinate dehydrogenase and fumarate reductase. In: Muller F. (Ed). Chemistry and Biochemistry of Flavoproteins (1990), CRC Press, Inc, Boca Raton FL 229-297
37. Ackrell B.A. Cytopathies involving mitochondrial complex II. Molecular Aspects of Medicine 23 (2002) 369-384
38. Gimenez-Roqueplo A.P., Favier J., Rustin P., et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. American Journal of Human Genetics 69 (2001) 1186-1197
39. Dahia P.L., Ross K.N., Wright M.E., et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 1 (2005) 72-80
40. Eisenhofer G., Huynh T.T., Pacak K., et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocrine-Related Cancer 11 (2004) 897-911
41. Lee S., Nakamura E., Yang H., et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8 (2005) 155-167
42. Selak M.A., Armour S.M., MacKenzie E.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7 (2005) 77-85
43. Gottlieb E., and Tomlinson I.P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nature Reviews. Cancer 5 (2005) 857-866
44. Heutink P., van Schothorst E.M., van der Mey, et al. Further localization of the gene for hereditary paragangliomas (PGL), and evidence for linkage in unrelated families. European Journal of Human Genetics 2 (1994) 148-158
45. Baysal B.E., van Schothorst E.M., Farr J.E., et al. Repositioning the hereditary paraganglioma critical region on chromosome band 11q23. Human Genetics 104 (1999) 219-225
46. Gimm O., Armanios M., Dziema H., et al. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Research 60 (2000) 6822-6825
47. Taschner P.E., Jansen J.C., Baysal B.E., et al. Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes, Chromosomes & Cancer 31 (2001) 274-281
48. Baysal B.E., Willett-Brozick J.E., Lawrence E.C., et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. Journal of Medical Genetics 39 (2002) 178-183
49. Astuti D., Hart-Holden N., Latif F., et al. Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clinical Endocrinology 59 (2003) 728-733
50. Neumann H.P., Pawlu C., Peczkowska M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. The Journal of the American Medical Association 292 (2004) 943-951 [Erratum in: The Journal of the American Medical Association 2004; 292: 1686]
51. Benn D.E., Gimenez-Roqueplo A.P., Reilly J.R., et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 827-836
52. Astrom K., Cohen J.E., Willett-Brozick J.E., et al. Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Human Genetics 113 (2003) 228-237
53. Dannenberg H., van Nederveen F.H., Abbou M., et al. Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. Journal of Clinical Oncology 23 (2005) 1894-1901
54. Milunsky J.M., Maher T.A., Michels V.V., et al. Novel mutations and the emergence of a common mutation in the SDHD gene causing familial paraganglioma. American Journal of Medical Genetics 100 (2001) 311-314
55. Amar L., Bertherat J., Baudin E., et al. Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology 23 (2005) 8812-8818
56. Hensen E.F., Jordanova E.S., van Minderhout I.J., et al. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23 (2004) 4076-4083
57. Dannenberg H., Dinjens W.N., Abbou M., et al. Frequent germ-line succinate dehydrogenase subunit D gene mutations in patients with apparently sporadic parasympathetic paraganglioma. Clinical Cancer Research 8 (2002) 2061-2066
58. Simi L., Sestini R., Ferruzzi P., et al. Phenotype variability of neural crest derived tumours in six Italian families segregating the same founder SDHD mutation Q109X. Journal of Medical Genetics 42 (2005) e52
59. Bertherat J., and Gimenez-Roqueplo A.P. New insights in the genetics of adrenocortical tumors, pheochromocytomas and paragangliomas. Hormone and Metabolic Research 37 (2005) 384-390
60. Pawlu C., Bausch B., and Neumann H.P. Mutations of the SDHB and SDHD genes. Familial Cancer 4 (2005) 49-54
61. McWhinney S.R., Pilarski R.T., Forrester S.R., et al. Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 5694-5699
62. Cascon A., Ruiz-Llorente S., Cebrian A., et al. G12S and H50R variations are polymorphisms in the SDHD gene. Genes, Chromosomes & Cancer 37 (2003) 220-221
63. Benn D.E., Croxson M.S., Tucker K., et al. Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 22 (2003) 1358-1364
64. Gimenez-Roqueplo A.P., Favier J., Rustin P., et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research 63 (2003) 5615-5621
65. Amar L., Servais A., Gimenez-Roqueplo A.P., et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 2110-2116
66. Dahia P.L. Evolving concepts in pheochromocytoma and paraganglioma. Current Opinion in Oncology 18 (2006) 1-8
67. Vanharanta S., Buchta M., McWhinney S.R., et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. American Journal of Human Genetics 74 (2004) 153-159
68. Beck O., Fassbender W.J., Beyer P., et al. Pheochromocytoma in childhood: implication for further diagnostic procedures. Acta Paediatrica 93 (2004) 1630-1634
69. Schiavi F., Boedeker C.C., Bausch B., et al. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. The Journal of the American Medical Association 294 (2005) 2057-2063 [Erratum in: The Journal of the American Medical Association 2006; 295: 628]
70. Baysal B.E., Willett-Brozick J.E., Filho P.A., et al. An Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma. Journal of Medical Genetics 41 (2004) 703-709
71. Muller U., Troidl C., and Niemann S. SDHC mutations in hereditary paraganglioma/pheochromocytoma. Familial Cancer 4 (2005) 9-12
72. Harris M., Winship I., and Spriggs M. Controversies and ethical issues in cancer-genetics clinics. The Lancet Oncology 6 (2005) 301-310
73. Barlow-Stewart K., and Burnett L. Ethical considerations in the use of DNA for the diagnosis of diseases. The Clinical Biochemist. Review 27 (2006) 53-61
74. Rosenthal M.S., and Pierce H.H. Inherited medullary thyroid cancer and the duty to warn: revisiting Pate v. Threlkel in light of HIPAA. Thyroid 15 (2005) 140-145
75. Evans J.P., Skrzynia C., and Burke W. The complexities of predictive genetic testing. British Medical Journal 322 (2001) 1052-1056
76. Brauch H., Hoeppner W., Jahnig H., et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. The Journal of Clinical Endocrinology and Metabolism 82 (1997) 4101-4104
77. Perren A., Barghorn A., Schmid S., et al. Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. Oncogene 21 (2002) 7605-7608
78. Cascon A., Ruiz-Llorente S., Fraga M.F., et al. Genetic and epigenetic profile of sporadic pheochromocytomas. Journal of Medical Genetics 41 (2004) e30
79. Elder E.E., Elder G., and Larsson C. Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. Journal of Surgical Oncology 89 (2005) 193-201
80. Elston M.S., Benn D., Robinson B.G., et al. An apparently sporadic paraganglioma with an SDHB gene germline mutation presenting at age 68 years. Internal Medicine Journal 36 (2006) 129-131
81. Young Jr. W.F., and Abboud A.L. Paraganglioma - all in the family. Editorial. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 790-792